Last10K.com

Acelity L.P. Inc. (1557939) SEC Filing 10-Q Quarterly report for the period ending Tuesday, June 30, 2015

Acelity L.P. Inc.

CIK: 1557939



ACELITY L.P. INC. REPORTS
SECOND QUARTER AND FIRST HALF FINANCIAL RESULTS FOR 2015
U.S. Advanced Wound Therapeutics revenue grew 10%


Second Quarter Financial Highlights

Revenue of $461.6 million, up 0.5% from the prior-year period and 5.1% on a constant currency basis

Revenue from Advanced Wound Therapeutics (“AWT”) devices grew double digits in the U.S. led by double digit volume increases compared to the prior-year period

Loss from continuing operations improved to $17.6 million compared to $153.8 million in the prior-year period

Adjusted EBITDA from continuing operations1 of $172.9 million, grew 2.9% versus the prior-year period and 5.6% on a constant currency basis, achieving an Adjusted EBITDA margin of 37.5%


Operational Highlights

Acelity’s revolutionary V.A.C.® Therapy technology achieves another record level of seasonally adjusted worldwide rental volumes

Announced two innovative product offerings in Europe: TIELLE® Non Adhesive, intended to manage a range of exudate levels and increase the comfort and ease for a patient; and the REVOLVE™ System which offers fast, efficient and secure fat tissue processing in a range of reconstructive procedures


Joe Woody, President and Chief Executive Officer, commented, “We delivered a strong financial performance in the second quarter, reflecting the power of Acelity’s growing global scale, innovative product portfolio and robust sales and service infrastructure. 

“On a consolidated basis, we delivered another consecutive quarter of year over year revenue growth. We have extended our leading position in North America and have also generated strong growth in emerging markets with double-digit increases across Latin America, China and India. In addition, we successfully introduced new products including Nanova™, TIELLE® and REVOLVE™ as well as negotiated future sales channels and distributors.

“Looking ahead, we believe we have the right strategies in place to ensure a resilient platform for sustainable growth. We continue to invest in innovation, further penetration within emerging markets, and development of markets served by our focus products in order to generate long-term value creation.”






The following information was filed by Acelity L.P. Inc. on Wednesday, July 29, 2015 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Acelity L.P. Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Acelity L.P. Inc..

Continue

Assess how Acelity L.P. Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Acelity L.P. Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2015 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Condensed Consolidated Balance Sheets
Condensed Consolidated Statements Of Cash Flows
Condensed Consolidated Statements Of Comprehensive Income (loss)
Condensed Consolidated Statements Of Comprehensive Income (loss) (parenthetical)
Condensed Consolidated Statements Of Operations
Accumulated Other Comprehensive Income (loss)
Accumulated Other Comprehensive Income (loss) (details)
Accumulated Other Comprehensive Income (loss) (tables)
Acquisitions And Divestitures (details)
Acquisitions And Divestitures (tables)
Acquisitions And Divestitures Acquisitions And Divestitures
Commitments And Contingencies
Commitments And Contingencies (details)
Derivative Financial Instruments And Fair Value Measurements
Derivative Financial Instruments And Fair Value Measurements (tables)
Derivative Financial Instruments And Fair Value Measurements - Derivative Financial Instruments (details)
Derivative Financial Instruments And Fair Value Measurements - Fair Value And Balance Sheet Locations (details)
Derivative Financial Instruments And Fair Value Measurements - Gain (loss) On Derivatives (details)
Guarantor Condensed Consolidating Financial Statements
Guarantor Condensed Consolidating Financial Statements (tables)
Guarantor Condensed Consolidating Financial Statements - Condensed Consolidated Balance Sheet (details)
Guarantor Condensed Consolidating Financial Statements - Condensed Consolidated Cash Flow (details)
Guarantor Condensed Consolidating Financial Statements - Condensed Consolidated Statement Of Operations And Comprehensive Income (loss) (details)
Long-term Debt
Long-term Debt (details)
Long-term Debt (tables)
Segment Information
Segment Information (details)
Segment Information (tables)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (details)
Summary Of Significant Accounting Policies (policies)
Supplemental Balance Sheet Data
Supplemental Balance Sheet Data (tables)
Supplemental Balance Sheet Data - Accounts Receivable, Net (details)
Supplemental Balance Sheet Data - Inventories, Net (details)

Material Contracts, Statements, Certifications & more

Acelity L.P. Inc. provided additional information to their SEC Filing as exhibits

CIK: 1557939
Form Type: 10-Q Quarterly Report
Accession Number: 0001557939-15-000046
Submitted to the SEC: Fri Jul 31 2015 4:39:55 PM EST
Accepted by the SEC: Fri Jul 31 2015
Period: Tuesday, June 30, 2015
Industry: Surgical And Medical Instruments And Apparatus

External Resources:

Bookmark the Permalink:
https://last10k.com/sec-filings/1557939/0001557939-15-000046.htm